Drug companies facing higher fees
EMA Highlights by Gary Finnegan – Pharmaceutical companies will have to pay more to have their new medicines evaluated, if the European Medicines Agency is to balance its… read more.
EMA Highlights by Gary Finnegan – Pharmaceutical companies will have to pay more to have their new medicines evaluated, if the European Medicines Agency is to balance its… read more.
EMA Highlights by Gary Finnegan – Several new medicines have been approved by the EMA’s influential Committee for Medicinal Products for Human Use (CHMP), including the first non-surgical… read more.
EMA Highlights by Eoghan McNeill – The EMA has published revised guidelines on the evaluation of anti-cancer medicines to take account of advances in research and new therapeutic… read more.